This is a single-arm, open-label, single-center, phase I study. The primary objective is to
evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or
refractory T-ALL/LBL, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.